Wolfram Brugger
Overview
Explore the profile of Wolfram Brugger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
2809
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Bergmann L, Brugger W, Herr W, Mackensen A, Multhoff G
Oncol Res Treat
. 2015 May;
38 Suppl 3:6-11.
PMID: 25966812
No abstract available.
22.
Henkes M, Finke J, Warnatz K, Ammann S, Zur Stadt U, Janka G, et al.
Ann Hematol
. 2014 Dec;
94(6):1057-60.
PMID: 25544030
No abstract available.
23.
Tassara M, Dohner K, Brossart P, Held G, Gotze K, Horst H, et al.
Blood
. 2014 May;
123(26):4027-36.
PMID: 24797300
The outcome of patients with acute myeloid leukemia who are older than 60 years has remained poor because of unfavorable disease characteristics and patient-related factors. The randomized German-Austrian AML Study...
24.
Mazieres J, Brugger W, Cappuzzo F, Middel P, Frosch A, Bara I, et al.
Lung Cancer
. 2013 Aug;
82(2):231-7.
PMID: 23972450
Introduction: The phase III SATURN study demonstrated that first-line maintenance erlotinib extended progression-free survival (PFS) and overall survival (OS) versus placebo in patients with advanced non-small cell lung cancer (NSCLC)....
25.
Brugger W, Ghielmini M
Oncologist
. 2013 Aug;
18(8):954-64.
PMID: 23900001
For patients with advanced indolent non-Hodgkin's lymphoma (NHL) or elderly patients with mantle cell lymphoma (MCL), the recently reported results of the German StiL NHL-1 2003 and the international BRIGHT...
26.
Gaidzik V, Schlenk R, Paschka P, Stolzle A, Spath D, Kuendgen A, et al.
Blood
. 2013 May;
121(23):4769-77.
PMID: 23632886
In this study, we evaluated the frequency and prognostic impact of DNMT3A mutations (DNMT3A(mut)) in 1770 younger adult patients with acute myeloid leukemia (AML) in the context of other genetic...
27.
Rummel M, Niederle N, Maschmeyer G, Banat G, von Grunhagen U, Losem C, et al.
Lancet
. 2013 Feb;
381(9873):1203-10.
PMID: 23433739
Background: Rituximab plus chemotherapy, most often CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone), is the first-line standard of care for patients with advanced indolent lymphoma, and for elderly patients with mantle-cell...
28.
Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, et al.
Nat Med
. 2012 Jul;
18(8):1254-61.
PMID: 22842478
IMA901 is the first therapeutic vaccine for renal cell cancer (RCC) consisting of multiple tumor-associated peptides (TUMAPs) confirmed to be naturally presented in human cancer tissue. We treated a total...
29.
30.
Brugger W, Thomas M
Lung Cancer
. 2012 Jan;
77(1):2-8.
PMID: 22281074
Treatment with receptor-tyrosine kinase inhibitors (TKIs) has improved progression-free and overall survival in patients with advanced non-small cell lung cancer (NSCLC). One major target for treatment with TKI is the...